ArticleNorthern clinics of Istanbul2020
Prognostic factors for survival in patients with gastric cancer: Single-centre experience.
Article in Northern clinics of Istanbul, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Pulmonary Arterial Hypertension and Cancer: Unveiling Parallels in Epidemiology, Clinical Pathways, and Therapeutic Strategies.Journal of market access & health policy · 2026Article
- Different Master Regulators Define Proximal and Distal Gastric Cancer: Insights into Prognosis and Opportunities for Targeted Therapy.Current oncology (Toronto, Ont.) · 2025Article
- Gastric Cancer Surgery Before and During the COVID-19 Pandemic in Turkey: A Multicenter Comparison of Prognostic Factors, Mortality, and Survival.Medicina (Kaunas, Lithuania) · 2025Article
- Upregulation of lncRNA ANRASSF1 is associated with the lymph node metastasis andBiomarkers in medicine · 2025Article
- The antioxidant and selective apoptotic activities of modified auraptene-loaded graphene quantum dot nanoparticles (M-AGQD-NP).Discover oncology · 2024Article
- Survival of Gastric Cancer Patients at a Tertiary Care Hospital in Eastern India: A Retrospective Data Analysis.Cureus · 2023Article
- Predictors of survival outcomes among patients with gastric cancer in a leading tertiary, teaching and referral hospital in Kenya.Cancer medicine · 2023Article
- Falling Trend in the Epidemiology of Gastric Cancer in Mississippi From 2003 to 2019: What Mississippi Got Right.Cureus · 2022Article
- Development of web-based dynamic nomogram to predict survival in patients with gastric cancer: a population-based study.Scientific reports · 2022Article
- Article
- Article
- Impact of Clinicopathological Features on Gastric Cancer Stage According to TNM Classification.In vivo (Athens, Greece)Article
- Clinicopathological Prognostic Factors Determining Outcomes of Treatment in Gastric Cancer Surgery.In vivo (Athens, Greece)Article
- Accuracy of Endoscopic Ultrasonography for Gastric Cancer Staging.Current health sciences journalArticle
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveWe aimed to investigate survival outcomes and survival-related prognostic factors in gastric cancer patients who were followed-up or received adjuvant therapy in our center.
methodsPatients with gastric cancer treated between 2005 and 2016 were evaluated retrospectively. We included 345 non-metastatic (stage I-III) gastric cancer patients in the study. The clinical, demographic, histologic data of the patients and treatment characteristics were obtained from the patient's files.
resultsWhile 50 patients were stage I, 94 patients were stage II, 201 patients were stage III. While 221 patients (64%) presenting with serosal or adjacent visceral organ invasion or with involved lymph nodes were treated with adjuvant chemoradiotherapy, 124 patients presenting with early-stage disease were followed after surgery. Median follow up time was 34 months (4-156 months). While the median overall survival (OS) was 51 months, median disease-free survival (DFS) was 35 months. Overall survival and disease-free survival rates for 1
conclusionMany different prognostic factors have been defined for gastric cancer. In concordance with the literature, we found T and N stages as prognostic factors in univariate and multivariate analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.